Release of Endogenous Opioids From Duodenal Enteroendocrine Cells Requires Trpm5
To access this article, please choose from the options below
Conflicts of interest Dr Margolskee has a personal financial interest in the form of stock ownership in the Redpoint Bio company, receives consulting fees from the Redpoint Bio company, and is an inventor on patents and patent applications that have been licensed to the Redpoint Bio company. The remaining authors disclose no conflicts.
Funding Supported in part by National Institutes of Health grants DC007399 and DK073248 (to B.M.) and DC03055 (to R.F.M.).
PII: S0016-5085(09)00356-4
doi:10.1053/j.gastro.2009.02.070
© 2009 AGA Institute. Published by Elsevier Inc. All rights reserved.

